Order Article Reprints

Lenci E, Cantini L, Pecci F, Cognigni V, Agostinelli V, Mentrasti G, Lupi A, Ranallo N, Paoloni F, Rinaldi S, et al. The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab. Journal of Clinical Medicine. 2021; 10(5):1005. https://doi.org/10.3390/jcm10051005

Lenci, Edoardo, Luca Cantini, Federica Pecci, Valeria Cognigni, Veronica Agostinelli, Giulia Mentrasti, Alessio Lupi, Nicoletta Ranallo, Francesco Paoloni, Silvia Rinaldi, and et al. 2021. "The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab" Journal of Clinical Medicine 10, no. 5: 1005. https://doi.org/10.3390/jcm10051005

Lenci, E., Cantini, L., Pecci, F., Cognigni, V., Agostinelli, V., Mentrasti, G., Lupi, A., Ranallo, N., Paoloni, F., Rinaldi, S., Nicolardi, L., Caglio, A., Aerts, S., Cortellini, A., Ficorella, C., Chiari, R., Di Maio, M., Dingemans, A.-M. C., Aerts, J. G. J. V., & Berardi, R. (2021). The Gustave Roussy Immune (GRIm)-Score Variation Is an Early-on-Treatment Biomarker of Outcome in Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Treated with First-Line Pembrolizumab. Journal of Clinical Medicine, 10(5), 1005. https://doi.org/10.3390/jcm10051005